Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Update

Lucid Diagnostics Inc. (NASDAQ:LUCD) was the target of a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 422,400 shares, a decrease of 61.2% from the October 15th total of 1,090,000 shares. Currently, 2.2% of the shares of the stock are short sold. Based on an average daily volume of 251,700 shares, the days-to-cover ratio is currently 1.7 days.

Lucid Diagnostics Trading Up 4.0 %

Lucid Diagnostics stock traded up $0.04 during midday trading on Wednesday, reaching $1.04. The company had a trading volume of 1,493,937 shares, compared to its average volume of 192,497. Lucid Diagnostics has a 12-month low of $0.63 and a 12-month high of $1.58. The firm’s fifty day simple moving average is $0.86 and its 200-day simple moving average is $0.84.

Lucid Diagnostics (NASDAQ:LUCD) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $0.98 million during the quarter. On average, sell-side analysts predict that Lucid Diagnostics will post -0.82 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Canaccord Genuity Group restated a “buy” rating and issued a $3.00 target price on shares of Lucid Diagnostics in a research note on Tuesday, August 13th. Needham & Company LLC reissued a “buy” rating and set a $2.50 price target on shares of Lucid Diagnostics in a research report on Tuesday, August 13th. Canaccord Genuity Group raised shares of Lucid Diagnostics to a “strong-buy” rating in a research note on Tuesday, August 13th. Finally, Ascendiant Capital Markets cut their target price on shares of Lucid Diagnostics from $7.50 to $7.25 and set a “buy” rating on the stock in a research report on Tuesday, September 10th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $3.94.

Institutional Investors Weigh In On Lucid Diagnostics

A hedge fund recently raised its stake in Lucid Diagnostics stock. Virtu Financial LLC grew its position in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) by 66.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 34,671 shares of the company’s stock after purchasing an additional 13,835 shares during the quarter. Virtu Financial LLC owned approximately 0.07% of Lucid Diagnostics worth $28,000 as of its most recent filing with the SEC. Institutional investors own 74.01% of the company’s stock.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.